This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

OKYO Pharma Dividend

Dividend criteriumcontroles 0/6

Belangrijke informatie

n/a

Dividendrendement

n/a

Uitbetalingsratio

Gemiddelde opbrengst industrie	1.5%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Winst per aandeel	-UK£0.26
Dividendrendementsvoorspelling	n/a

Recente dividendupdates

Geen updates

Recent updates

Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

Nov 26

Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

Jan 27

Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

Sep 22

We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

Mar 17

We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

Dec 02

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if OKYO's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if OKYO's dividend payments have been increasing.

Dividendrendement versus markt

OKYO Pharma Dividendrendement versus markt

Hoe verhoudt OKYO dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (OKYO)	n/a
Markt onderkant 25% (GB)	2.1%
Markt Top 25% (GB)	5.7%
Gemiddelde industrie (Biotechs)	1.5%
Analist prognose (OKYO) (tot 3 jaar)	n/a

Opmerkelijk dividend: Unable to evaluate OKYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate OKYO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as OKYO has not reported any payouts.

This company listing is no longer active

OKYO Pharma Dividend

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente dividendupdates

Recent updates

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

High number of new and inexperienced directors

High number of new and inexperienced directors

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

High number of new and inexperienced directors

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

Independent Non-Executive Director Kunwar Shailubhai has left the company

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

OKYO Pharma Limited announced that it has received £5.437104 million in funding

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend